BAYER 

On The Frontline of AI-driven Transformation of Drug Discovery

1200px-Logo_Bayer.svg.png

Steady growth in the “AI for Drug Discovery sector” can be observed in terms of the substantially increased amount of venture capital pouring into the AI-driven biotech startups (around $1.9B in 2020 alone, so far), the increasing number of research partnerships between leading pharma organizations and AI-biotechs, and AI-technology vendors, a continuing pipeline of industry developments, research breakthroughs, and proof of concept studies, as well as exploding attention of leading media and consulting companies to the topic of AI in pharma and healthcare. 

Bayer appears to be leading the pack of big pharma companies focused on developing the data-driven “AI-first” strategy of the pharmaceutical innovation.

Bayer On The Frontline of AI-driven Transformation of Drug Discovery

10-Page Report

AI Partnerships and Programs at Bayer